Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01153607 | Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers | PHASE1 | COMPLETED | 24 | — | — | Jun 1, 2010 | Oct 1, 2011 | Jan 21, 2013 | 2 | Finland, Sweden |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1006578 | DRUG | Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET |
Inclusion Criteria: * All: * Males or females aged \>/- 50 years * Participants must be able to understand the information provided on purpose and conduct of the clinical study, must be capable of giving fully informed consent in writing, and have read and signed the informed consent prior to ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Hologic, Inc. | HOLX | 1 | NA | Undisclosed |
| Intelligent Bio Solutions Inc. | INBS | 1 | — | Undisclosed |
| HeartFlow, Inc. | HTFL | 1 | NA | Rosuvastatin |
| GE Healthcare Technologies Inc. | GEHC | 2 | NA | Undisclosed |
| Unity Health Toronto | UBX | 1 | — | Undisclosed |